Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Mar;7(1):1-2.
doi: 10.4103/0976-3147.172156.

Intravenous thrombolysis: Still an important tool in the management of severe ischemic stroke patients

Jukka T Saarinen  1
Affiliations

Intravenous thrombolysis: Still an important tool in the management of severe ischemic stroke patients

Jukka T Saarinen. J Neurosci Rural Pract. 2016 Jan-Mar.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Kalkonde YV, Deshmukh MD, Sahane V, Puthran J, Kakarmath S, Agavane V, et al. Stroke is the leading cause of death in rural Gadchiroli, India: A prospective community-based study. Stroke. 2015;46:1764–8. - PubMed
    1. Dharmasaroja PA, Muengtaweepongsa S. Outcomes of patients with large middle cerebral infarct treated with and without intravenous thrombolysis. J Neurosci Rural Pract. 2016;7:36–9. - PMC - PubMed
    1. Lima FO, Furie KL, Silva GS, Lev MH, Camargo EC, Singhal AB, et al. Prognosis of untreated strokes due to anterior circulation proximal intracranial arterial occlusions detected by use of computed tomography angiography. JAMA Neurol. 2014;71:151–7. - PubMed
    1. Saarinen JT, Sillanpää N, Rusanen H, Hakomäki J, Huhtala H, Lähteelä A, et al. The mid-M1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis. Eur J Neurol. 2012;19:1121–7. - PubMed
    1. IST. Collaborative Group. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352–63. - PMC - PubMed

LinkOut - more resources